US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Super League Gaming Inc.

5.53

-0.1150-2.04%

Pre-market: 5.550.0250+0.45%04:00 EDT

Volume:140.46K

Turnover:776.01K

Market Cap:13.66M

PE:-0.45

High:5.79

Open:5.61

Low:5.28

Close:5.64

52wk High:61.44

52wk Low:2.12

Shares:2.47M

Float Shares:2.02M

Volume Ratio:0.71

T/O Rate:6.95%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-12.3857

EPS(LYR):-40.4307

ROE:-503.98%

ROA:-64.67%

PB:1.06

PE(LYR):-0.14

Loading ...

Overview Company News Filings

Press Release: Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results

Study Results of Orelabrutinib in Patients with SLE Published in the Journal of Autoimmunity

Press Release: Vor Bio Appoints David Zaccardelli to Board of Directors

Super League Enterprise initiated with a Buy at ThinkEquity

Super League Enterprise files to sell 1.07M shares of common stock for holders

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

Super League becomes U.S. ad sales partner for Play.Works CTV advergaming inventory

Maxim Group Sticks to Its Buy Rating for Super League Enterprise (SLE)

Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

IMMUNEONCO-B Shares Surge Over 7% on Positive Early Trial Data for SLE Drug Candidate

Johnson And Johnson Autoimmune Trial Data And What It Means For JNJ

Simply Wall St.

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Super League names Anthony Alexander EVP of revenue

Super League Strengthens Commercial Leadership With Appointment of Anthony Alexander as Executive Vice President of Revenue

THOMSON REUTERS

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/SLE/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":5.525,"timestamp":1790798400000,"preClose":5.64,"halted":0,"volume":140460,"hourTrading":{"tag":"盘前","latestPrice":5.55,"preClose":5.525,"latestTime":"04:00 EDT","volume":104,"amount":577.1999999999999,"timestamp":1790841608401,"change":0.025,"changeRate":0.004525,"amplitude":0},"delay":0,"changeRate":-0.020390070921985696,"floatShares":2020495,"shares":2473200,"eps":-12.385672,"marketStatus":"Pre-Mkt","change":-0.115,"latestTime":"10-01 04:59:05 EDT","open":5.61,"high":5.788,"low":5.28,"amount":776005.82316,"amplitude":0.090071,"askPrice":5.85,"askSize":50,"bidPrice":4.94,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-12.385672,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":5.525,"preHourTrading":{"tag":"盘前","latestPrice":5.55,"preClose":5.525,"latestTime":"04:00 EDT","volume":104,"amount":577.1999999999999,"timestamp":1790841608401,"change":0.025,"changeRate":0.004525,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":5.55,"preClose":5.525,"latestTime":"19:30 EDT","volume":1219,"amount":6676.5544,"timestamp":1790811001931,"change":0.025,"changeRate":0.004525,"amplitude":0.034389},"volumeRatio":0.7097093653125519},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":2020495,"roa":"-64.67%","roe":"-503.98%","lyrEps":-40.430703,"volumeRatio":0.7097093653125519,"shares":2473200,"dividePrice":0,"high":5.788,"amplitude":0.090071,"preClose":5.64,"low":5.28,"week52Low":2.12,"pbRate":"1.06","psRate":"1.17","week52High":61.44,"institutionHeld":0,"latestPrice":5.525,"committee":0.333333,"eps":-12.385672,"divideRate":0,"volume":140460,"delay":0,"ttmEps":-12.385672,"open":5.61,"prevYearClose":7.326,"prevWeekClose":5.03,"prevMonthClose":5.525,"prevQuarterClose":5.525,"fiveDayClose":5.26,"twentyDayClose":3.73,"sixtyDayClose":2.93},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"SLE","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-2.7},{"market":"US","date":"2026-05-15","symbol":"SLE","fiscalQuarterEnding":"2026/03","expectedEps":-2.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-1.77},{"market":"US","date":"2026-03-27","symbol":"SLE","fiscalQuarterEnding":"2025/12","expectedEps":-3.12,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774584000000,"reportTimeType":"pre","actualEps":-9.44},{"market":"US","date":"2026-01-23","symbol":"SLE","defaultRemindTime":1769178600000,"type":"split","dateTimestamp":1769144400000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2025-11-13","symbol":"SLE","fiscalQuarterEnding":"2025/09","expectedEps":-2.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-2.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1782792000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2026-09-29","current":-0.44608,"percent":0.212737,"low":-0.738945,"twenty":-0.349642,"median":-0.269443,"eighty":-0.213599,"high":-0.044016,"avg":-0.283143,"sd":0.114905,"marketCap":7644991},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387},{"date":"2025-06-20","current":-0.204904,"twenty":-0.346791,"median":-0.280097,"eighty":-0.210029,"marketCap":3197521},{"date":"2025-06-27","current":-0.222294,"twenty":-0.344958,"median":-0.279367,"eighty":-0.209283,"marketCap":3468896},{"date":"2025-07-03","current":-0.240225,"twenty":-0.342139,"median":-0.277573,"eighty":-0.209588,"marketCap":3748716},{"date":"2025-07-11","current":-0.314762,"twenty":-0.339781,"median":-0.277296,"eighty":-0.209879,"marketCap":4911855},{"date":"2025-07-18","current":-0.242124,"twenty":-0.33814,"median":-0.276346,"eighty":-0.210021,"marketCap":3778350},{"date":"2025-07-25","current":-0.228831,"twenty":-0.337327,"median":-0.276269,"eighty":-0.210038,"marketCap":3570911},{"date":"2025-08-01","current":-0.243781,"twenty":-0.33696,"median":-0.274358,"eighty":-0.210831,"marketCap":3804205},{"date":"2025-08-08","current":-0.233576,"twenty":-0.336712,"median":-0.273838,"eighty":-0.212858,"marketCap":3644959},{"date":"2025-08-15","current":-0.231876,"twenty":-0.33606,"median":-0.271353,"eighty":-0.213354,"marketCap":3618418},{"date":"2025-08-22","current":-0.221928,"twenty":-0.335323,"median":-0.269787,"eighty":-0.212104,"marketCap":3535981},{"date":"2025-08-29","current":-0.23749,"twenty":-0.333566,"median":-0.269388,"eighty":-0.213354,"marketCap":3783930},{"date":"2025-09-05","current":-0.192157,"twenty":-0.332345,"median":-0.269014,"eighty":-0.213084,"marketCap":3061642},{"date":"2025-09-12","current":-0.207719,"twenty":-0.332042,"median":-0.268116,"eighty":-0.210012,"marketCap":3309592},{"date":"2025-09-19","current":-0.247639,"twenty":-0.331721,"median":-0.267958,"eighty":-0.20982,"marketCap":3945637},{"date":"2025-09-26","current":-0.362878,"twenty":-0.332345,"median":-0.267958,"eighty":-0.210012,"marketCap":5781732},{"date":"2025-10-03","current":-0.272683,"twenty":-0.334082,"median":-0.268394,"eighty":-0.210038,"marketCap":4344654},{"date":"2025-10-10","current":-0.24891,"twenty":-0.332345,"median":-0.268116,"eighty":-0.210567,"marketCap":3965889},{"date":"2025-10-17","current":-0.321134,"twenty":-0.33627,"median":-0.269014,"eighty":-0.211856,"marketCap":5116629},{"date":"2025-10-24","current":-0.188157,"twenty":-0.335429,"median":-0.268704,"eighty":-0.211856,"marketCap":2997912},{"date":"2025-10-31","current":-0.131167,"twenty":-0.334082,"median":-0.267958,"eighty":-0.20982,"marketCap":2089890},{"date":"2025-11-07","current":-0.105839,"twenty":-0.332345,"median":-0.267719,"eighty":-0.208727,"marketCap":1686325},{"date":"2025-11-14","current":-0.110362,"twenty":-0.332042,"median":-0.267321,"eighty":-0.207583,"marketCap":1758390},{"date":"2025-11-21","current":-0.081028,"twenty":-0.331721,"median":-0.26512,"eighty":-0.206427,"marketCap":1285354},{"date":"2025-11-28","current":-0.659255,"twenty":-0.334597,"median":-0.266863,"eighty":-0.206708,"marketCap":10457765},{"date":"2025-12-05","current":-0.720254,"twenty":-0.337177,"median":-0.26748,"eighty":-0.207472,"marketCap":11425396},{"date":"2025-12-12","current":-0.614194,"twenty":-0.34219,"median":-0.267958,"eighty":-0.207492,"marketCap":9742959},{"date":"2025-12-19","current":-0.474574,"twenty":-0.347254,"median":-0.268394,"eighty":-0.207537,"marketCap":7528174},{"date":"2025-12-26","current":-0.4608,"twenty":-0.349022,"median":-0.269014,"eighty":-0.207719,"marketCap":7309663},{"date":"2026-01-02","current":-0.447318,"twenty":-0.351152,"median":-0.26966,"eighty":-0.207719,"marketCap":7095801},{"date":"2026-01-09","current":-0.503223,"twenty":-0.354793,"median":-0.269873,"eighty":-0.208261,"marketCap":7982631},{"date":"2026-01-16","current":-0.526743,"twenty":-0.360917,"median":-0.271353,"eighty":-0.208641,"marketCap":8355727},{"date":"2026-01-23","current":-0.388481,"twenty":-0.368101,"median":-0.272683,"eighty":-0.20874,"marketCap":6162476},{"date":"2026-01-30","current":-0.377954,"twenty":-0.369864,"median":-0.273838,"eighty":-0.208765,"marketCap":5995491},{"date":"2026-02-06","current":-0.254616,"twenty":-0.369341,"median":-0.274166,"eighty":-0.209154,"marketCap":4038966},{"date":"2026-02-13","current":-0.250952,"twenty":-0.368944,"median":-0.274262,"eighty":-0.209588,"marketCap":3980851},{"date":"2026-02-20","current":-0.244846,"twenty":-0.368353,"median":-0.273838,"eighty":-0.20982,"marketCap":3883993},{"date":"2026-02-27","current":-0.219812,"twenty":-0.367557,"median":-0.272683,"eighty":-0.209529,"marketCap":3486877},{"date":"2026-03-06","current":-0.285756,"twenty":-0.365648,"median":-0.271783,"eighty":-0.20982,"marketCap":4532940},{"date":"2026-03-13","current":-0.266522,"twenty":-0.361898,"median":-0.272212,"eighty":-0.210012,"marketCap":4227838},{"date":"2026-03-20","current":-0.285756,"twenty":-0.360355,"median":-0.272267,"eighty":-0.210038,"marketCap":4532940},{"date":"2026-03-27","current":-0.254616,"twenty":-0.358486,"median":-0.271712,"eighty":-0.210567,"marketCap":4038966},{"date":"2026-04-02","current":-0.208821,"twenty":-0.355643,"median":-0.27114,"eighty":-0.210302,"marketCap":3312533},{"date":"2026-04-10","current":-0.260127,"twenty":-0.354839,"median":-0.269787,"eighty":-0.210302,"marketCap":5389056},{"date":"2026-04-17","current":-0.281981,"twenty":-0.354827,"median":-0.26986,"eighty":-0.211608,"marketCap":5841796},{"date":"2026-04-24","current":-0.268594,"twenty":-0.354771,"median":-0.270513,"eighty":-0.212842,"marketCap":5564456},{"date":"2026-05-01","current":-0.267882,"twenty":-0.354343,"median":-0.269886,"eighty":-0.213819,"marketCap":5549706},{"date":"2026-05-08","current":-0.295375,"twenty":-0.352599,"median":-0.271247,"eighty":-0.213857,"marketCap":6119281},{"date":"2026-05-15","current":-0.286915,"twenty":-0.351648,"median":-0.272111,"eighty":-0.213857,"marketCap":5944027},{"date":"2026-05-22","current":-0.634562,"twenty":-0.354827,"median":-0.272503,"eighty":-0.213857,"marketCap":13032642},{"date":"2026-05-29","current":-0.249501,"twenty":-0.354781,"median":-0.272503,"eighty":-0.213857,"marketCap":5124247},{"date":"2026-06-05","current":-0.248769,"twenty":-0.35473,"median":-0.272212,"eighty":-0.214067,"marketCap":5109220},{"date":"2026-06-12","current":-0.241452,"twenty":-0.352795,"median":-0.271911,"eighty":-0.214067,"marketCap":4958949},{"date":"2026-06-18","current":-0.230477,"twenty":-0.35201,"median":-0.271247,"eighty":-0.214405,"marketCap":4733542},{"date":"2026-06-26","current":-0.225356,"twenty":-0.351152,"median":-0.269886,"eighty":-0.214489,"marketCap":4628352},{"date":"2026-07-02","current":-0.229746,"twenty":-0.35011,"median":-0.269715,"eighty":-0.214549,"marketCap":4718515},{"date":"2026-07-10","current":-0.220234,"twenty":-0.349224,"median":-0.269201,"eighty":-0.214489,"marketCap":4523163},{"date":"2026-07-17","current":-0.207795,"twenty":-0.349022,"median":-0.268594,"eighty":-0.214067,"marketCap":4267702},{"date":"2026-07-24","current":-0.19682,"twenty":-0.348987,"median":-0.268161,"eighty":-0.213857,"marketCap":4042295},{"date":"2026-07-31","current":-0.20121,"twenty":-0.348468,"median":-0.267958,"eighty":-0.213493,"marketCap":4132458},{"date":"2026-08-07","current":-0.202674,"twenty":-0.34754,"median":-0.267882,"eighty":-0.210977,"marketCap":4162512},{"date":"2026-08-14","current":-0.245842,"twenty":-0.347244,"median":-0.2674,"eighty":-0.211398,"marketCap":5049112},{"date":"2026-08-21","current":-0.293824,"twenty":-0.347244,"median":-0.26748,"eighty":-0.210977,"marketCap":6506742},{"date":"2026-08-28","current":-0.291642,"twenty":-0.347002,"median":-0.26792,"eighty":-0.211398,"marketCap":6458407},{"date":"2026-09-04","current":-0.269443,"twenty":-0.345822,"median":-0.267958,"eighty":-0.211454,"marketCap":5966822},{"date":"2026-09-11","current":-0.349817,"twenty":-0.347254,"median":-0.268274,"eighty":-0.211683,"marketCap":7746698},{"date":"2026-09-18","current":-0.352113,"twenty":-0.348716,"median":-0.268804,"eighty":-0.212737,"marketCap":7797552},{"date":"2026-09-25","current":-0.410289,"twenty":-0.349431,"median":-0.269388,"eighty":-0.213388,"marketCap":9085843},{"date":"2026-09-29","current":-0.345224,"twenty":-0.349642,"median":-0.269443,"eighty":-0.213599,"marketCap":7644991}],"updateTime":1790816652972},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657636586","title":"Press Release: Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636586","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636586?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017600,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. & EDMONTON, Alberta----August 06, 2026--Aurinia Pharmaceuticals Inc.  today announced financial results for the three and six months ended June 30, 2026 and provided an update on recent business progress.Financial Results--  Total Revenue: For the three and six months ended June 30, 2026, total. revenue was $83.2 million and $160.9 million, up 19% and 21%,respectively, from $70.0 million and $132.5 million, respectively, in the. --  Net Product Sales: For the three and six months ended June 30,2026, net product sales of LUPKYNIS, the first FDA-approved oral. therapy for the treatment of adult patients with active lupus. nephritis, were $79.4 million and $153.0 million, up 19% and 21%,--  License, Collaboration and Royalty Revenue: For the three and. six months ended June 30, 2026, license, collaboration and royalty. respectively, from $3.4 million and $5.9 million, respectively, in. from $21.5 million and $44.9 million, respectively, in the same periods. respectively, fr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","R","BK4232","BK4022","BK4139","AUPH","LU2065732104.USD","SLE","BK4077","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657825638","title":"Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657825638","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657825638?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014000,"startTime":"0","endTime":"0","summary":"-- At the EULAR 2026 Congress in June, the Company presented. promising initial single target dose data, which demonstrated the. potential for immune reset in a refractory and heterogeneous SLE. population. CLN-978 also improved lab markers of disease activity. and demonstrated deep, dose-dependent B cell depletion in. peripheral blood as well as dose-dependent recovery with a. -- In Q4 2026, the Company plans to share initial multi-dose regimen. data. The Company also plans to begin Phase 2 expansion in early. 2027 in patients with SLE and in patients with lupus nephritis.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","ITP","BK4139","BK4077","SLE","BK4199","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657620235","title":"Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657620235","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657620235?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:01","pubTimestamp":1785873660,"startTime":"0","endTime":"0","summary":"Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338774/0/en/Dianthus-Therapeutics-Highlights-Recent-Business-Achievements-and-Reports-Q2-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4546","BK4161","BK4007","DM","BK4139","SLE","LENZ","BK4539","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650138444","title":"Study Results of Orelabrutinib in Patients with SLE Published in the Journal of Autoimmunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2650138444","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650138444?lang=en_us&edition=fundamental","pubTime":"2026-07-10 21:00","pubTimestamp":1783688400,"startTime":"0","endTime":"0","summary":"BEIJING, July  10, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), today announced that the Journal of Autoimmunity has published results from a clinical study evaluating orelabr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/10/3325537/0/en/Study-Results-of-Orelabrutinib-in-Patients-with-SLE-Published-in-the-Journal-of-Autoimmunity.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","IE0031619046.USD","BK4124","IE00B19Z4B17.USD","BK4077","SRI","IE00B7SZL793.SGD","IE00B66KJ199.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649954937","title":"Press Release: Vor Bio Appoints David Zaccardelli to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2649954937","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649954937?lang=en_us&edition=fundamental","pubTime":"2026-07-08 04:01","pubTimestamp":1783454460,"startTime":"0","endTime":"0","summary":"BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zacc","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4077","R","RA","VOR","BK4139","SLE","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647840373","title":"Super League Enterprise initiated with a Buy at ThinkEquity","url":"https://stock-news.laohu8.com/highlight/detail?id=2647840373","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647840373?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:15","pubTimestamp":1782728137,"startTime":"0","endTime":"0","summary":"ThinkEquity initiated coverage of Super League Enterprise (SLE) with a Buy rating and $6 price target Super League is an advertising and gaming med...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-initiated-with-a-buy-at-thinkequity-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-initiated-with-a-buy-at-thinkequity-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643777213","title":"Super League Enterprise files to sell 1.07M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2643777213","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643777213?lang=en_us&edition=fundamental","pubTime":"2026-06-13 05:20","pubTimestamp":1781299209,"startTime":"0","endTime":"0","summary":"17:17 EDT Super League Enterprise (SLE) files to sell 1.07M shares of common stock for holders Published first on TheFly – the ultimate source for ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-files-to-sell-1-07m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-files-to-sell-1-07m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642728928","title":"Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642728928","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642728928?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175600,"startTime":"0","endTime":"0","summary":"Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310326/0/en/Climb-Bio-Announces-Initial-Phase-1b-Data-Demonstrating-On-Target-Clinical-Activity-for-Budoprutug-in-Immune-Thrombocytopenia-at-EHA-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4199","SLE","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442360","title":"Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442360","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642442360?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:30","pubTimestamp":1781091000,"startTime":"0","endTime":"0","summary":"CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) CLN-978 data from the first RA mul","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/10/3309602/0/en/Cullinan-Therapeutics-Shares-New-Clinical-Data-Across-Its-Portfolio-of-T-Cell-Engager-Programs-Targeting-CD19-and-BCMA-in-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","LU0963586101.USD","RA","IE00B66KJ199.SGD","BK4139","BK4199","CGEM","BK4006","CRS","SLE","IE0031619046.USD","LU2065731478.USD","ITP","BK4187","BK4077","IE00B19Z4B17.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642460083","title":"Super League becomes U.S. ad sales partner for Play.Works CTV advergaming inventory","url":"https://stock-news.laohu8.com/highlight/detail?id=2642460083","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642460083?lang=en_us&edition=fundamental","pubTime":"2026-06-09 21:00","pubTimestamp":1781010022,"startTime":"0","endTime":"0","summary":"Super League entered a U.S. ad sales partnership with Play.Works for connected TV advergaming inventory.Deal gives U.S. advertisers managed access to playable ads, rewarded video across a network reaching more than 100 million households.Play.Works network runs over 150 million monthly ad impressions, with a 95% view-through rate; average game sessions exceed 19 minutes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL7gtFJ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014039.USD","IE00BKPKM429.USD","SG9999014021.USD","IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","SLE","IE00BGHQF748.EUR","LU2210150020.SGD","BK4585","SG9999014013.SGD","IE00BN0W2V16.EUR","BK4588","LU0314104364.USD","IE00BN0W2T93.GBP","BK4077","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642460683","title":"Maxim Group Sticks to Its Buy Rating for Super League Enterprise (SLE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642460683","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642460683?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:35","pubTimestamp":1781008529,"startTime":"0","endTime":"0","summary":"In a report released today, Jack Vander Aarde from Maxim Group reiterated a Buy rating on Super League Enterprise, with a price target of $15.00. V...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-its-buy-rating-for-super-league-enterprise-sle-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-its-buy-rating-for-super-league-enterprise-sle-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641484542","title":"Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2641484542","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641484542?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:31","pubTimestamp":1780921860,"startTime":"0","endTime":"0","summary":"First regulatory approval for Sjgren’s disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statist","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/08/3308123/0/en/Telitacicept-Receives-NMPA-Approval-for-the-Treatment-of-Sj%C3%B6gren-s-Disease-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","RA","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641290111","title":"Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2641290111","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641290111?lang=en_us&edition=fundamental","pubTime":"2026-06-06 17:15","pubTimestamp":1780737300,"startTime":"0","endTime":"0","summary":"Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 Deep, dose-dependent B ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/06/3307681/0/en/Cullinan-Therapeutics-Presents-Initial-Clinical-Data-for-CLN-978-a-CD19xCD3-T-Cell-Engager-at-the-EULAR-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS","BK4006","LU2065731478.USD","BK4187","IE00B66KJ199.SGD","IE00B19Z4B17.USD","LU0963586101.USD","IE00B7SZL793.SGD","RA","IE0031619046.USD","CGEM","BK4077","BK4139","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180244677","title":"IMMUNEONCO-B Shares Surge Over 7% on Positive Early Trial Data for SLE Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1180244677","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180244677?lang=en_us&edition=fundamental","pubTime":"2026-06-05 14:30","pubTimestamp":1780641052,"startTime":"0","endTime":"0","summary":"Shares of IMMUNEONCO-B (01541) have risen more than 7%. At the time of writing, the stock is up 6.11% to HK$3.3, with a turnover of HK$3.9031 million. Catalyst for the Move On June 4th, the company...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4585","BK4588","SLE","01541","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640168705","title":"Johnson And Johnson Autoimmune Trial Data And What It Means For JNJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2640168705","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640168705?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:41","pubTimestamp":1780576860,"startTime":"0","endTime":"0","summary":"Johnson & Johnson (NYSE:JNJ) reported positive topline Phase 2 results for nipocalimab in systemic lupus erythematosus (SLE) and Sjögren's disease.\nThe JASMINE study in SLE met its primary endpoint with clinically meaningful reductions in disease activity.\nExploratory analyses from the DAHLIAS study in Sjögren's disease showed strong responses in patients with high autoantibody and IgG levels.\nThe company plans to continue clinical development of nipocalimab for these high unmet need...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/139677-main-header/1756253951625","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/139677-main-header/1756253951625"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/johnson-and-johnson-autoimmune-trial-data-and-what-it-means","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/johnson-and-johnson-autoimmune-trial-data-and-what-it-means","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B3PB1722.GBP","LU0320765646.SGD","LU1551013342.USD","LU0122379950.USD","LU2112291526.USD","LU0345770308.USD","SLE","LU1585245621.USD","LU1066051498.USD","LU1935042991.SGD","IE00BKVL7J92.USD","LU0210528500.USD","IE00BGHQF631.EUR","LU2023250330.USD","IE00BN8TJ469.HKD","BK4592","LU1506573853.SGD","LU1778281490.HKD","IE0001KFT4U8.USD","LU1032466523.USD","BK4585","LU2236285917.USD","SG9999001440.SGD","IE00B3T34201.USD","IE00B4R5TH58.HKD","LU2129689514.USD","JNJ","LU0203345920.USD","BK4534","SG9999002224.SGD","LU0792757196.USD","IE000SO60NU8.SGD","LU1244550221.USD","IE00BVYPNW00.USD","IE00B7SZLL34.SGD","LU0964807845.USD","LU2133065610.SGD","LU2471134796.USD","LU2505996509.AUD","BK4588","LU1983299246.USD","LU2896262040.SGD","BK4568","BK4550","LU1032955483.USD","LU1261432733.SGD","IE000WAW04H5.SGD","SG9999002232.USD","LU1228905037.USD","IE00BDGV0183.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157248","title":"Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157248","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640157248?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:30","pubTimestamp":1780576200,"startTime":"0","endTime":"0","summary":"FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as outpatient administration in community hospitals Continued d","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/04/3306754/24675/en/Fate-Therapeutics-Showcases-Data-from-FT819-and-FT839-Programs-at-the-European-Congress-of-Rheumatology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR","LU2065731478.USD","EPV","CRS","BK4230","LU0963586101.USD","BK4022","BK4006","FATE","IE0031619046.USD","IE00B66KJ199.SGD","BK4077","IE00B7SZL793.SGD","SLE","BK4139","BK4187","IE00B19Z4B17.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640913176","title":"EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2640913176","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640913176?lang=en_us&edition=fundamental","pubTime":"2026-06-04 13:00","pubTimestamp":1780549200,"startTime":"0","endTime":"0","summary":"Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/04/3306500/0/en/EULAR-2026-Dapirolizumab-Pegol-Shows-Potential-to-Reduce-Flare-Rates-and-Maintain-Disease-Control-in-Systemic-Lupus-Erythematosus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1496350171.SGD","IE00BD4GTW91.USD","LU2456880835.USD","LU0786609619.USD","BK4523","BK4585","LU0157215616.USD","LU2346227817.USD","LU1066051498.USD","LU1674673691.USD","LU2500361329.USD","LU1366192091.USD","LU0077335932.USD","LU2237443549.SGD","LU1066051225.USD","BK4077","IE00BMG7P694.USD","LU1066051811.HKD","LU1935042488.USD","IE00BMG7P819.SGD","BK4588","LU1935043023.USD","LU1935043536.SGD","LU0170899867.USD","IE00BMG7P926.USD","IE00BD4GTT62.SGD","IE00BD4GTV84.USD","BK4214","LU2236285917.USD","LU2083900584.USD","LU1935042991.SGD","LU2237443978.SGD","APC","LU0882574139.USD","LU0314104364.USD","PEG","LU0053666078.USD","LU1674673428.USD","BK4208","IFN","LU0149725797.USD","LU2237443622.USD","LU2420271590.USD","SLE","LU1066053197.SGD","LU1366333091.USD","LU2237443382.USD","IE00BMG7P587.USD","LU1778281490.HKD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640029659","title":"Super League names Anthony Alexander EVP of revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2640029659","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640029659?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:05","pubTimestamp":1780491926,"startTime":"0","endTime":"0","summary":"Super League named Anthony Alexander executive vice president of revenue, effective June 8, 2026.Alexander will lead global sales, set revenue strategy, manage brand and agency ties, commercialize audience, data, technology assets.He previously served as chief revenue officer at Livewire, a global gaming marketing agency.Earlier, he spent over a decade at Playwire, rising to EVP of global sales, running its direct advertising business.The appointment follows Super League’s May 2026 acquisition of the Misfits Ads business, expanding its client base, capabilities, revenue mix.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original content used to generate this news brief on June 03, 2026, and i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL4VsQYv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640375902","title":"Super League Strengthens Commercial Leadership With Appointment of Anthony Alexander as Executive Vice President of Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2640375902","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640375902?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:00","pubTimestamp":1780491601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA6CBCHV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640503952","title":"Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus","url":"https://stock-news.laohu8.com/highlight/detail?id=2640503952","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640503952?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:00","pubTimestamp":1780318800,"startTime":"0","endTime":"0","summary":"Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, mor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304433/32920/en/Exagen-Announces-Publication-of-Systematic-Review-Confirming-Robust-Real-World-Performance-of-AVISE-Lupus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","XGN","BK4077","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":102,"code":"91000000","status":"200"}]}}